CLINICAL_TRIALS
trial_result
· 2017-06-21
Clinical Trial Update: Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis [Phase 2]
Summary
An extension study of REGN88 (SAR153191) in ankylosing spondylitis was terminated in Phase 2, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Ankylosing Spondylitis | Phase 2 | Status: TERMINATED | Results posted: 2017-06-21